(Q37983498)

26 August 2017

Chemotherapy for the biliary tract cancers: moving toward improved survival time (English)

1 reference

26 August 2017

1 reference

Angelo Zullo

3

0 references

Paolo Marchetti

object named as

Paolo Marchetti

8

0 references

author name string

Adriana Romiti

1

1 reference

26 August 2017

Chiara D'Antonio

2

1 reference

26 August 2017

Ida Sarcina

4

1 reference

26 August 2017

Roberta Di Rocco

5

1 reference

26 August 2017

Viola Barucca

6

1 reference

26 August 2017

Valeria Durante

7

1 reference

26 August 2017

language of work or name

1 reference

1 September 2012

1 reference

Journal of gastrointestinal cancer

26 August 2017

1 reference

26 August 2017

43

1 reference

26 August 2017

3

1 reference

26 August 2017

396-404

1 reference

https://scigraph.springernature.com/pub.10.1007/s12029-012-9369-2

26 August 2017

0 references

cites work

Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Descriptive epidemiology of cholangiocarcinoma in Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

K-ras gene mutation in gall bladder carcinomas and dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high-incidence area.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

21 January 2018

Biliary tract cancers.

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiot

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Genetics of biliary tract cancers and emerging targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Treatment of colorectal cancer. Current guidelines and future prospects for drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Phase II study of S-1 in patients with advanced biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Efficacy and safety of S-1 monotherapy in patients with advanced biliary tract adenocarcinoma: retrospective analysis of 162 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

S-1 monotherapy in patients with advanced biliary tract cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Review of gemcitabine in biliary tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

The EGF receptor system as a target for antitumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Phase II study of erlotinib in patients with advanced biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Improved operative and survival outcomes of surgical treatment for hilar cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Prognostic factors of patients with advanced gallbladder carcinoma following aggressive surgical resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

The number of metastatic lymph nodes in extrahepatic bile duct carcinoma as a prognostic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Indication for postoperative adjuvant therapy in biliary carcinoma based on analysis of recurrence and survival after surgical resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Extrahepatic biliary duct carcinoma: the continuing evolution of multidisciplinary management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Role of adjuvant chemoradiotherapy for ampulla of Vater cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9369-2

Carcinoma of the major intrahepatic and the extrahepatic bile ducts exclusive of the papilla of Vater

21 January 2018

1 reference

12 December 2020

Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma

1 reference

12 December 2020

Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report

1 reference

12 December 2020

Nuclear survivin expression predicts poor outcome in cholangiocarcinoma.

1 reference

12 December 2020

Genetic alterations in gallbladder adenoma, dysplasia and carcinoma

1 reference

12 December 2020

The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy

1 reference

12 December 2020

Pathological aspects of cholangiocarcinoma

1 reference

12 December 2020

Association of Bcl-2 protein expression with gallbladder carcinoma differentiation and progression and its relation to apoptosis

1 reference

12 December 2020

Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer.

1 reference

12 December 2020

Liver, gallbladder, extrahepatic bile ducts, and pancreas

1 reference

12 December 2020

Cancers of the gallbladder and biliary ducts.

1 reference

12 December 2020

A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma

1 reference

12 December 2020

Impact of postoperative irradiation after non-curative resection of hilar biliary cancer

1 reference

12 December 2020

Radiation therapy in extrahepatic bile duct carcinoma

1 reference

12 December 2020

A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma

1 reference

12 December 2020

5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract

1 reference

12 December 2020

10.1007/S12029-012-9369-2

Identifiers

DOI

1 reference

26 August 2017

1 reference